Suchen
United Therapeutics Corp
UTHRZur Watchlist hinzufügen
500.350USD
-2.350-0.47%
Handelsschluss 09-15 16:00（ET）
21.35BMarktkapitalisierung
17.09KGV TTM
mehr Informationen über United Therapeutics Corp Unternehmen
United Therapeutics Corporation is a pharmaceutical company. The Company markets and sells commercial therapies to treat pulmonary arterial hypertension (PAH): Tyvaso DPI (treprostinil) Inhalation Powder (Tyvaso DPI); Tyvaso (treprostinil) Inhalation Solution (nebulized Tyvaso), which includes the Tyvaso Inhalation System; Remodulin (treprostinil) Injection (Remodulin); Orenitram (treprostinil) Extended-Release Tablets (Orenitram); and Adcirca (tadalafil) Tablets (Adcirca). Tyvaso DPI and nebulized Tyvaso are also approved to treat pulmonary hypertension associated with interstitial lung disease (PH-ILD). It also markets and sells an oncology product, Unituxin (dinutuximab) Injection for the treatment of high-risk neuroblastoma, and the Remunity Pump for Remodulin. Tyvaso DPI is a drug-device combination product that incorporates the dry powder formulation technology and Dreamboat inhalation device technology used in MannKind’s Afrezza (insulin human) Inhalation Powder product.
United Therapeutics Corp Profil
BörsenkürzelUTHR
Name des UnternehmensUnited Therapeutics Corp
IPO-datumJun 17, 1999
CEORothblatt (Martine A)
Anzahl der mitarbeiter1305
WertpapierartOrdinary Share
GeschäftsjahresendeJun 17
Addresse1000 Spring St
StadtSILVER SPRING
BörseNASDAQ OMX - NASDAQ BASIC
LandUnited States of America
Postleitzahl20910
Telefon13016089292
Websitehttps://www.unither.com/
BörsenkürzelUTHR
IPO-datumJun 17, 1999
CEORothblatt (Martine A)
Führungskräfte von United Therapeutics Corp
Name
Name/Position
Position
Aktienbesitz
Veränderung
Dr. Martine A. Rothblatt, J.D., Ph.D.
Dr. Martine A. Rothblatt, J.D., Ph.D.
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
690.66K
--
Mr. Paul A. Mahon, J.D.
Mr. Paul A. Mahon, J.D.
Executive Vice President, General Counsel, and Corporate Secretary
Executive Vice President, General Counsel, and Corporate Secretary
45.17K
--
Mr. Richard A. Giltner
Mr. Richard A. Giltner
Independent Director
Independent Director
21.88K
+5.99%
Mr. Michael Benkowitz
Mr. Michael Benkowitz
President and Chief Operating Officer
President and Chief Operating Officer
21.39K
+87.62%
Prof. Nilda Mesa, J.D.
Prof. Nilda Mesa, J.D.
Independent Director
Independent Director
5.68K
+11.45%
The Hon. Dr. Louis W. Sullivan, M.D.
The Hon. Dr. Louis W. Sullivan, M.D.
Independent Director
Independent Director
4.44K
+14.64%
Mr. Christopher Patusky, J.D.
Mr. Christopher Patusky, J.D.
Lead Independent Vice Chairman of the Board
Lead Independent Vice Chairman of the Board
3.24K
+20.06%
Ms. Jan Malcolm
Ms. Jan Malcolm
Independent Director
Independent Director
450.00
+72.22%
Mr. Raymond C. (Ray) Kurzweil, J.D.
Mr. Raymond C. (Ray) Kurzweil, J.D.
Independent Director
Independent Director
--
--
Mr. Christopher A. Causey
Mr. Christopher A. Causey
Independent Director
Independent Director
--
--
Mehr Anzeigen
Name
Name/Position
Position
Aktienbesitz
Veränderung
Dr. Martine A. Rothblatt, J.D., Ph.D.
Dr. Martine A. Rothblatt, J.D., Ph.D.
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
690.66K
--
Mr. Paul A. Mahon, J.D.
Mr. Paul A. Mahon, J.D.
Executive Vice President, General Counsel, and Corporate Secretary
Executive Vice President, General Counsel, and Corporate Secretary
45.17K
--
Mr. Richard A. Giltner
Mr. Richard A. Giltner
Independent Director
Independent Director
21.88K
+5.99%
Mr. Michael Benkowitz
Mr. Michael Benkowitz
President and Chief Operating Officer
President and Chief Operating Officer
21.39K
+87.62%
Prof. Nilda Mesa, J.D.
Prof. Nilda Mesa, J.D.
Independent Director
Independent Director
5.68K
+11.45%
The Hon. Dr. Louis W. Sullivan, M.D.
The Hon. Dr. Louis W. Sullivan, M.D.
Independent Director
Independent Director
4.44K
+14.64%
Häufig gestellte Fragen
Wer sind die fünf größten Anteilseigner von United Therapeutics Corp?
Die fünf größten Anteilseigner von United Therapeutics Corp sind: Dr. Martine A. Rothblatt, J.D., Ph.D.
Wie viele Institutionen halten Anteile an United Therapeutics Corp (UTHR)?
Mit Stand vom 2026Q1 halten 1548 Institutionen Anteile an United Therapeutics Corp, mit einem Gesamtmarktwert von etwa 42.91M, was 101.10% der Gesamtanteile entspricht. Im Vergleich zum 2025Q4 ist der institutionelle Aktienbesitz um -1413631.00 gestiegen.
Was ist die größte Einnahmequelle von United Therapeutics Corp?
Am 2026Q1 erzielte das Geschäft mit Tyvaso DPI für United Therapeutics Corp den höchsten Umsatz in Höhe von 326.60M, was 41.70% des Gesamtumsatzes entspricht.